Education: Professor of gene therapy and associate professor of immunology at Uppsala University.
Experience: Magnus Essand (born 1964) has been working as a professor of gene therapy at Uppsala University since 2009, before which he has worked at the American National Cancer Institute (NCI). He has published 95 scientific articles and has been a leading (first/last) author on 53 of these. He has on numerous occasions been awarded prizes for his work and has received large research grants from the Swedish Research Council, Horizon 2020, the Cancer Foundation, the Child Cancer Foundation, the Knut & Alice Wallenberg Foundation, the Sjöberg Foundation and others. He is currently a sponsor of two clinical studies in immuno-oncology. Professor Essand is the co-founder of Elicera AB.
Dependency: Magnus Essand is dependent in relation to the company, its senior executives and major shareholders.
Shares: 3 314 475 (incl. related parties).